Efficacy and Safety of Epoetin Alfa in Critically Ill Patients

2007544 citationsJournal Articlebronze Open Access

Authors

Howard L. Corwin · Dartmouth–Hitchcock Medical Center

Andrew Gettinger · Dartmouth–Hitchcock Medical Center

Timothy C. Fabian · University of Tennessee Health Science Center

Addison K. May · Vanderbilt University Medical Center

Ronald G. Pearl · Stanford University

Stephen O. Heard · UMass Memorial Medical Center

Robert An

Abstract

The use of epoetin alfa does not reduce the incidence of red-cell transfusion among critically ill patients, but it may reduce mortality in patients with trauma. Treatment with epoetin alfa is associated with an increase in the incidence of thrombotic events. (ClinicalTrials.gov number, NCT00091910 [ClinicalTrials.gov].).

Topics & Keywords

Erythropoietin and Anemia Treatment Blood transfusion and management Hemoglobinopathies and Related Disorders

UN Sustainable Development Goals

No poverty

Publication Details

Published in: New England Journal of Medicine

Volume 357, Issue 10, pp. 965-976

DOI: 10.1056/nejmoa071533

Field-Weighted Citation Impact: 26.67